Stevanato Group Q4 2024 Earnings Report
Key Takeaways
Stevanato Group reported Q4 2024 revenue of €330.6 million, a 3% increase year-over-year. The Biopharmaceutical and Diagnostic Solutions segment grew 7%, offsetting a 16% decline in the Engineering segment. Gross profit margin declined to 29.7%, impacted by vial destocking, while operating profit margin improved to 20.2%. Adjusted EPS was €0.19, reflecting cost management initiatives and strong performance in high-value solutions.
Q4 revenue grew 3% year-over-year to €330.6 million.
Biopharmaceutical and Diagnostic Solutions segment increased 7%, offsetting a 16% decline in Engineering.
Gross profit margin declined by 210 basis points to 29.7%, impacted by vial destocking.
Adjusted diluted EPS increased to €0.19, driven by cost controls and strong demand for syringes.
Stevanato Group
Stevanato Group
Stevanato Group Revenue by Segment
Forward Guidance
Stevanato Group expects continued revenue growth in FY 2025, driven by demand for high-value solutions and ongoing capacity expansion. Cost management initiatives will continue to support margin improvements.
Positive Outlook
- Projected FY 2025 revenue between €1,160 million and €1,190 million.
- Adjusted EBITDA forecasted to range from €293 million to €306.3 million.
- Adjusted diluted EPS expected to be between €0.51 and €0.55.
- Continued demand growth in high-value syringes and biologics-related products.
- Operational efficiencies and cost-saving initiatives to improve margins.
Challenges Ahead
- Engineering segment challenges expected to persist in the near term.
- Vial destocking effects may continue to impact revenue mix.
- Higher capital expenditures expected due to facility expansions.
- Macroeconomic uncertainties could affect customer demand.
- Foreign exchange volatility may impact revenue and profitability.
Revenue & Expenses
Visualization of income flow from segment revenue to net income